Scotiabank analyst Sung Ji Nam maintained a Buy rating on BioNano Genomics (BNGO – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $1.33.
Ji Nam covers the Healthcare sector, focusing on stocks such as Guardant Health, BioNano Genomics, and Illumina. According to TipRanks, Ji Nam has an average return of -2.0% and a 49.54% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioNano Genomics with a $11.00 average price target.
See the top stocks recommended by analysts >>
BNGO market cap is currently $50.55M and has a P/E ratio of -0.28.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNano Genomics (BNGO) Company Description:
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
Read More on BNGO:
- Bionano Genomics reports Q3 revenue $9.32M, consensus $9.08M
- Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
- Bionano Genomics announces OGM was included in a medical school textbook
- Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023
- Bionano Genomics files to sell 12.2M shares of common stock for holders
